Overview

• Sanofi will pay $129 per share in cash, valuing Blueprint Medicines at $9.1 billion, a 27% premium on the previous Friday’s closing price.
• Blueprint’s Avapritinib, approved in the US and EU, is currently the only treatment for systemic mastocytosis, bolstering Sanofi’s rare immunological disease portfolio.
• Blueprint shareholders may receive up to $400 million in additional milestone payments, potentially raising the total deal value to $9.5 billion.
• Sanofi expects to complete the acquisition in the third quarter of 2025 with no material impact on its full-year financial guidance.
• The acquisition underpins Sanofi’s transformation into a leading immunology-focused drugmaker valued at about €107 billion.